Timothy A Chan

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-8 pubmed publisher
    ..Our results suggest that the genomic landscape of lung cancers shapes response to anti-PD-1 therapy. ..
  2. Chowell D, Morris L, Grigg C, Weber J, Samstein R, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359:582-587 pubmed publisher
    ..Our results have important implications for predicting response to ICB and for the design of neoantigen-based therapeutic vaccines. ..
  3. Yang W, Lee K, Srivastava R, Kuo F, Krishna C, Chowell D, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;: pubmed publisher
  4. Havel J, Chowell D, Chan T. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150 pubmed publisher
    ..A better understanding of how these variables cooperate to affect tumour-host interactions is needed to optimize the implementation of precision immunotherapy. ..
  5. Samstein R, Lee C, Shoushtari A, Hellmann M, Shen R, Janjigian Y, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202-206 pubmed publisher
    ..These data indicate that TMB is associated with improved survival in patients receiving ICI across a wide variety of cancer types, but that there may not be one universal definition of high TMB. ..
  6. Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, SESHAN V, et al. Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell. 2018;34:256-270.e5 pubmed publisher
    ..We also identify fusion genes and disrupted signaling pathways that may drive disease pathogenesis. ..
  7. Snyder A, Chan T. Immunogenic peptide discovery in cancer genomes. Curr Opin Genet Dev. 2015;30:7-16 pubmed publisher
    ..The methods for neoantigen prediction will be reviewed here, along with the most important examples of their use in the field of oncology. ..
  8. Lee C, Yelensky R, Jooss K, Chan T. Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. Trends Immunol. 2018;39:536-548 pubmed publisher
    ..Here, we review our understanding of neoantigens and discuss new developments in the quest to use them in cancer immunotherapy. ..
  9. Riaz N, Morris L, Havel J, Makarov V, Desrichard A, Chan T. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28:411-9 pubmed publisher
    ..This review summarizes the key discoveries leading up to this important conclusion and discusses possible applications of neoantigens in cancer therapy. ..

More Information

Publications20

  1. Rizvi N, Chan T. Immunotherapy and Oncogenic Pathways: The PTEN Connection. Cancer Discov. 2016;6:128-9 pubmed publisher
    ..These results shed light on the intricate interplay between oncogenic pathways and antitumor immune response. ..
  2. Desrichard A, Snyder A, Chan T. Cancer Neoantigens and Applications for Immunotherapy. Clin Cancer Res. 2016;22:807-12 pubmed publisher
    ..Specifically, these neoantigens could be useful both as predictors of immune checkpoint blockade therapy response and/or incorporated in therapeutic vaccination strategies. ..
  3. Walsh L, Alvarez M, Sabio E, Reyngold M, Makarov V, Mukherjee S, et al. An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. Cell Rep. 2017;20:1623-1640 pubmed publisher
    ..Our findings suggest that identifying and targeting keystone proteins, like TRIM25, can effectively collapse transcriptional hierarchies necessary for metastasis formation, thus representing an innovative cancer intervention strategy. ..
  4. Dalin M, Katabi N, Persson M, Lee K, Makarov V, Desrichard A, et al. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nat Commun. 2017;8:1197 pubmed publisher
    ..Our findings indicate that MECA is a fusion-driven disease, nominate TGFBR3-PLAG1 as a hallmark of MECA, and provide a framework for future diagnostic and therapeutic research in this lethal cancer. ..
  5. Gong Y, Schumacher S, Wu W, Tang F, Beroukhim R, Chan T. Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia. 2017;19:75-83 pubmed publisher
    ..Thus, like genes at the nodal points of growth arrest pathways such as p53, the PARK2 tumor suppressor is able to exert its antiproliferative effects by regulating both cell cycle progression and programmed cell death. ..
  6. Samstein R, Chan T. Dissecting microsatellite instability in colorectal cancer: one size does not fit all. Genome Med. 2017;9:45 pubmed publisher
    ..See related research by Sveen et al. 10.1186/s13073-017-0434-0. ..
  7. Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171:934-949.e16 pubmed publisher
    ..Temporal changes in intratumoral TCR repertoire revealed expansion of T cell clones in the setting of neoantigen loss. Comprehensive genomic profiling data in this study provide insight into nivolumab's mechanism of action. ..
  8. Turcan S, Makarov V, Taranda J, Wang Y, Fabius A, Wu W, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2018;50:62-72 pubmed publisher
    ..These findings have substantial implications for understanding of mutant IDH function and for optimizing therapeutic approaches to targeting IDH-mutant tumors. ..
  9. Roy D, Walsh L, Desrichard A, Huse J, Wu W, Gao J, et al. Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. Cancer Cell. 2016;29:737-750 pubmed publisher
    ..This comprehensive approach uncovered several 9p loss-specific prognostic markers, validated existing ones, and redefined the impact of CDKN2A loss in LGG. ..
  10. Mandal R, Chan T. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov. 2016;6:703-13 pubmed publisher
    ..Recent progress in these areas has been promising and has created a framework for precision immune-oncology. Cancer Discov; 6(7); 703-13. ©2016 AACR. ..
  11. Ortiz B, Fabius A, Wu W, Pedraza A, Brennan C, Schultz N, et al. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proc Natl Acad Sci U S A. 2014;111:8149-54 pubmed publisher